Literature DB >> 19920101

Use of oral N-acetylcysteine for protection of melanocytic nevi against UV-induced oxidative stress: towards a novel paradigm for melanoma chemoprevention.

Agnessa Gadeliya Goodson1, Murray A Cotter, Pamela Cassidy, Mark Wade, Scott R Florell, Tong Liu, Kenneth M Boucher, Douglas Grossman.   

Abstract

PURPOSE: Induction of oxidative stress has been implicated in UV-induced melanoma. We sought to determine whether the antioxidant N-acetylcysteine (NAC) could be safely administered to protect melanocytic nevi from the oxidative stress resulting from acute UV exposure. EXPERIMENTAL
DESIGN: Patients at increased risk for melanoma were recruited from a screening clinic. Induction and detection of oxidative stress (reactive oxygen species and glutathione depletion) was optimized in nevi following ex vivo UV irradiation. Nevi were removed from patients before, and following, oral ingestion of a single (1,200 mg) dose of NAC, and then these nevi were UV irradiated (4,000 J/m(2)).
RESULTS: Oxidative stress was induced in nevi 24 to 48 hours following ex vivo UV irradiation. A single oral dose of NAC was well tolerated in all patients (n = 72). Basal levels of reduced glutathione and the NAC metabolite cysteine were well correlated between similar-appearing nevi from the same patient and were significantly increased in nevi removed 3 hours after NAC ingestion compared with nevi removed before drug ingestion. In approximately half (9 of 19) of patients tested, UV-induced glutathione depletion was attenuated in the postdrug (compared with predrug) nevus.
CONCLUSIONS: NAC can be safely administered to patients for the purpose of modulating UV-induced oxidative stress in nevi. This study suggests the feasibility of patients taking NAC prophylactically before acute UV exposure, to prevent pro-oncogenic oxidative stress in nevi and ultimately reduce long-term melanoma risk.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19920101      PMCID: PMC2787788          DOI: 10.1158/1078-0432.CCR-09-1890

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  44 in total

1.  Oxidation potentials of human eumelanosomes and pheomelanosomes.

Authors:  Alexander Samokhvalov; Lian Hong; Yan Liu; Jacob Garguilo; Robert J Nemanich; Glenn S Edwards; John D Simon
Journal:  Photochem Photobiol       Date:  2005 Jan-Feb       Impact factor: 3.421

2.  Structural basis for recognition and repair of the endogenous mutagen 8-oxoguanine in DNA.

Authors:  S D Bruner; D P Norman; G L Verdine
Journal:  Nature       Date:  2000-02-24       Impact factor: 49.962

Review 3.  Gamma-glutamyltransferase, atherosclerosis, and cardiovascular disease: triggering oxidative stress within the plaque.

Authors:  Michele Emdin; Alfonso Pompella; Aldo Paolicchi
Journal:  Circulation       Date:  2005-10-04       Impact factor: 29.690

Review 4.  Green tea and the skin.

Authors:  Stephen Hsu
Journal:  J Am Acad Dermatol       Date:  2005-06       Impact factor: 11.527

5.  Sunscreen application at the beach.

Authors:  J Lademann; S Schanzer; H Richter; R V Pelchrzim; L Zastrow; K Golz; W Sterry
Journal:  J Cosmet Dermatol       Date:  2004-04       Impact factor: 2.696

6.  Increasing burden of melanoma in the United States.

Authors:  Eleni Linos; Susan M Swetter; Myles G Cockburn; Graham A Colditz; Christina A Clarke
Journal:  J Invest Dermatol       Date:  2009-01-08       Impact factor: 8.551

7.  Effect of (-)-epigallocatechin gallate, the main constituent of green tea, on lung metastasis with mouse B16 melanoma cell lines.

Authors:  S Taniguchi; H Fujiki; H Kobayashi; H Go; K Miyado; H Sadano; R Shimokawa
Journal:  Cancer Lett       Date:  1992-07-31       Impact factor: 8.679

8.  Sampling of melanocytic nevi for research purposes: a prospective, pilot study to determine effect on diagnosis.

Authors:  Scott R Florell; Bruce R Smoller; Kenneth M Boucher; Douglas Grossman; Ronald M Harris; Glen M Bowen; Sancy A Leachman
Journal:  J Am Acad Dermatol       Date:  2008-11       Impact factor: 11.527

9.  Human acquired naevi are clonal.

Authors:  W A Robinson; M Lemon; A Elefanty; M Harrison-Smith; N Markham; D Norris
Journal:  Melanoma Res       Date:  1998-12       Impact factor: 3.599

10.  Female rats are protected against oxidative stress during copper deficiency.

Authors:  Isabelle Bureau; Elyett Gueux; Andrzej Mazur; Edmond Rock; Anne-Marie Roussel; Yves Rayssiguier
Journal:  J Am Coll Nutr       Date:  2003-06       Impact factor: 3.169

View more
  14 in total

1.  A Phase II Randomized Placebo-Controlled Trial of Oral N-acetylcysteine for Protection of Melanocytic Nevi against UV-Induced Oxidative Stress In Vivo.

Authors:  Pamela B Cassidy; Tong Liu; Scott R Florell; Matthew Honeggar; Sancy A Leachman; Kenneth M Boucher; Douglas Grossman
Journal:  Cancer Prev Res (Phila)       Date:  2016-12-05

Review 2.  Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials.

Authors:  Joanne M Jeter; Tawnya L Bowles; Clara Curiel-Lewandrowski; Susan M Swetter; Fabian V Filipp; Zalfa A Abdel-Malek; Larisa J Geskin; Jerry D Brewer; Jack L Arbiser; Jeffrey E Gershenwald; Emily Y Chu; John M Kirkwood; Neil F Box; Pauline Funchain; David E Fisher; Kari L Kendra; Ashfaq A Marghoob; Suephy C Chen; Michael E Ming; Mark R Albertini; John T Vetto; Kim A Margolin; Sherry L Pagoto; Jennifer L Hay; Douglas Grossman; Darrel L Ellis; Mohammed Kashani-Sabet; Aaron R Mangold; Svetomir N Markovic; Frank L Meyskens; Kelly C Nelson; Jennifer G Powers; June K Robinson; Debjani Sahni; Aleksandar Sekulic; Vernon K Sondak; Maria L Wei; Jonathan S Zager; Robert P Dellavalle; John A Thompson; Martin A Weinstock; Sancy A Leachman; Pamela B Cassidy
Journal:  Cancer       Date:  2018-10-03       Impact factor: 6.860

3.  Feasibility of serial biopsies of large dysplastic nevi as a melanoma chemoprevention model.

Authors:  Christopher D Lao; Timothy Johnson; Vernon K Sondak; Lori Lowe; David S L Kim; Lili Zhao; Mark Naftanel; Stephen Olsen; Dean E Brenner
Journal:  J Am Acad Dermatol       Date:  2011-06       Impact factor: 11.527

4.  High expression of GCLC is associated with malignant melanoma of low oxidative phenotype and predicts a better prognosis.

Authors:  Dimitrios Mougiakakos; Riki Okita; Takashi Ando; Christoph Dürr; Jules Gadiot; Jiro Ichikawa; Robert Zeiser; Christian Blank; C Christian Johansson; Rolf Kiessling
Journal:  J Mol Med (Berl)       Date:  2012-01-17       Impact factor: 4.599

5.  A Randomized Double-blind Placebo-controlled Trial of Oral Aspirin for Protection of Melanocytic Nevi Against UV-induced DNA Damage.

Authors:  Nwanneka Okwundu; Hafeez Rahman; Tong Liu; Scott R Florell; Kenneth M Boucher; Douglas Grossman
Journal:  Cancer Prev Res (Phila)       Date:  2021-11-08

6.  PKM2 inhibitor shikonin suppresses TPA-induced mitochondrial malfunction and proliferation of skin epidermal JB6 cells.

Authors:  Wenjuan Li; Joan Liu; Yunfeng Zhao
Journal:  Mol Carcinog       Date:  2012-12-19       Impact factor: 4.784

7.  Mitochondrial oxidative stress drives tumor progression and metastasis: should we use antioxidants as a key component of cancer treatment and prevention?

Authors:  Federica Sotgia; Ubaldo E Martinez-Outschoorn; Michael P Lisanti
Journal:  BMC Med       Date:  2011-05-23       Impact factor: 8.775

8.  Potent antioxidative and UVB protective effect of water extract of Eclipta prostrata L.

Authors:  Chin-Feng Chan; Wen-Ying Huang; Hong-Yi Guo; Bo Rong Wang
Journal:  ScientificWorldJournal       Date:  2014-02-09

9.  Selenium for the prevention of cutaneous melanoma.

Authors:  Pamela B Cassidy; Heidi D Fain; James P Cassidy; Sally M Tran; Philip J Moos; Kenneth M Boucher; Russell Gerads; Scott R Florell; Douglas Grossman; Sancy A Leachman
Journal:  Nutrients       Date:  2013-03-07       Impact factor: 5.717

10.  Outpatient Follow-up and Secondary Prevention for Melanoma Patients.

Authors:  Ryan G Gamble; Daniel Jensen; Andrea L Suarez; Anne H Hanson; Lauren McLaughlin; Jodi Duke; Robert P Dellavalle
Journal:  Cancers (Basel)       Date:  2010-06-07       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.